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J-SERIES PROSTAGLANDIN-ETHANOLAMIDES AS NOVEL THERAPEUTICS
FOR SKIN AND/OR ORAL DISORDERS
Related Application Information
This application claims the benefit of and priority to U.S. Provisional Patent
Application Serial No. 62/303,679, filed March 4, 2016, the disclosure of which is
incorporated herein by reference in their entirety.
Field of the Invention
The present invention relates to methods of using and administering J-series
prostaglandin-ethanolamides and prodrugs thereof for treatment and/or prevention of skin
and/or oral disorders.
Background of the Invention
15deoxy, ∆ 12.14 Prostaglandin J2 (15dPGJ2-EA; see U.S. Patent No. 9,328,060) is
a novel molecule that was discovered and synthesized by our research group. We determined
that 15dPGJ2-EA induced skin tumor cell death while causing little harm to non-tumor skin
cells.
The endoplasmic reticulum (ER) is an organelle that is primarily responsible for
folding proteins. ER stress occurs when the demand for protein folding exceeds the cells
capacity to fold proteins leading to an accumulation in unfolded or misfolded proteins. In
response to the accumulation of malformed proteins the cell attempts to relieve the stress or
initiates death if the total cellular stress is insurmountable.
Summary of the Invention
In an aspect of the invention, provided is a compound, 15-deoxy '14-prostagladin
J2-ethanolamide (15-deoxy A '
4PGJ2-EA), of formula (I), or a prodrug or derivative thereof,
and salts thereof:
as well as pharmaceutical compositions comprising a therapeutically effective amount of 15-
deoxy A 2 '1 PGJ2-EA, or a prodrug or derivative thereof, and salts thereof, and a
pharmaceutically acceptable carrier. Also provided are methods of preventing and/or treating
a skin disorder and/or oral disorder in a subject, the method comprising administering a
compound and/or composition described herein.
Embodiments of the present invention also provide kits comprising the compounds
and/or compositions described herein and a container suitable for housing or delivery of the
compounds and/or composition within a common packaging, and instructions for use of the
same for the prevention or treatment of skin and/or oral disorders.
Brief Description of the Drawings
Fig. 1 is a graph illustrating that ER stress is elevated in virus-infected cells, but not in
normal cells. Exposure to ER stress inducing agents causes the total cellular level of ER
stress to exceed the death threshold in virus-infected cells, thereby causing selective toxicity.
Fig. 2 is a graph illustrating that 15dPMJ2 is selectively toxic. Tumorigenic and non-
tumorigenic keratinocytes were treated with different concentrations of 15dPMJ2, vehicle, or
were untreated for 1 hours. Cell viability was detected by conducting MTS experiments.
Data represent the mean ± SEM of three independent experiments and are expressed as the
percent of the untreated cells. *P < 0.01 .
Fig. 3A is a graph illustrating that 15dPMJ2 inhibits solid tumor growth and increases
ER stress. Tumors grown in C57BL/6 mice were either untreated (UT), vehicle treated
(VEH), or treated with 0.5 mg/kg 15dPMJ2 for 5 days. Tumor weights were determined.
# P < 0.01 compared to untreated; *P < 0.01 compared to vehicle treated (one-way ANOVA
r
with Tukey's post-hoc test).
Fig. 3B shows images of CHOP- 10 levels (top images) examined in the excised
tumors (bottom images) as described in Fig. 3A.
Fig. 4A is a schematic showing CRPV experimental design. Scars will be induced in
animals on the dorsal surface of the rabbit. CRPV will be applied to the scar at day 3 (0.4
weeks). Papilloma growth will be monitored for 3 weeks followed by drug treatment for 5
weeks. Recurrence will be monitored for 3 additional weeks.
Fig. 4B is a schematic in regard to determination of viral DNA concentration. CRPV
or empty vector (EV) DNA will be applied to the left (L) or right (R) scars at a concentration
of 10 g and 20 g.
Fig. 4C is a schematic in regard to vehicle identification. 15dPMJ2 (PMJ) will be
dissolved in various vehicles and topically applied to scars and normal skin. Vehicle alone
will also be applied topically as a negative control.
Fig. 4D is a schematic in regard to therapeutic activity. 15dPMJ2, salicylic acid or
vehicle will be applied to the papillomas and the uninvolved skin.
Detailed Description
In the following detailed description, embodiments of the present invention are
described in detail to enable practice of the invention. Although the invention is described
with reference to these specific embodiments, it should be appreciated that the invention can
be embodied in different forms and should not be construed as limited to the embodiments set
forth herein. Rather, these embodiments are provided so that this disclosure will be thorough
and complete, and will fully convey the scope of the invention to those skilled in the art. All
publications cited herein are incorporated by reference in their entireties for their teachings.
The invention includes numerous alternatives, modifications, and equivalents as will
become apparent from consideration of the following detailed description.
As used herein, the singular forms "a," "an" and "the" are intended to include the
plural forms as well, unless the context clearly indicates otherwise. For example, "a" cell can
mean one cell or a plurality of cells.
It will be understood that although the terms "first," "second," "third," "a)," "b)," and
"c)," etc. may be used herein to describe various elements of the invention should not be
limited by these terms. These terms are only used to distinguish one element of the invention
from another. Thus, a first element discussed below could be termed a element aspect, and
similarly, a third without departing from the teachings of the present invention. Thus, the
terms "first," "second," "third," "a)," "b)," and "c)," etc. are not intended to necessarily
convey a sequence or other hierarchy to the associated elements but are used for
identification purposes only. The sequence of operations (or steps) is not limited to the order
presented in the claims or figures unless specifically indicated otherwise.
Also as used herein, "and/or" refers to and encompasses any and all possible
combinations of one or more of the associated listed items, as well as the lack of
combinations when interpreted in the alternative ("or").
Furthermore, the term "about," as used herein when referring to a measurable value
such as an amount of a compound or agent of this invention, dose, time, temperature, and the
like, is meant to encompass variations of ± 20%, ± 10%, ± 5%, ± 1%, ± 0.5%, or even ± 0.1%
of the specified amount. For example, "about X" where X is a measurable value, is meant to
include X as well as variations of ± 20%, ± 10%, ± 5%, ± 1%, ± 0.5%, or even ± 0.1% of
X. A range provided herein for a measureable value may include any other range and/or
individual value therein.
As used herein, the transitional phrase "consisting essentially of means that the scope
of a claim is to be interpreted to encompass the specified materials or steps recited in the
claim, and those that do not materially affect the basic and novel characteristic(s) of the
claimed invention.
As used herein, "one or more" can mean one, two, three, four, five, six, seven, eight,
nine, ten or more, up to any number.
Unless otherwise defined, all terms (including technical and scientific terms) used
herein have the same meaning as commonly understood by one of ordinary skill in the art to
which this invention belongs. It will be further understood that terms, such as those defined
in commonly used dictionaries, should be interpreted as having a meaning that is consistent
with their meaning in the context of the present application and relevant art and should not be
interpreted in an idealized or overly formal sense unless expressly so defined herein. The
terminology used in the description of the invention herein is for the purpose of describing
particular embodiments only and is not intended to be limiting of the invention. All
publications, patent applications, patents and other references mentioned herein are
incorporated by reference in their entirety. In case of a conflict in terminology, the present
specification is controlling.
The term "administering" or "administered" as used herein is meant to include
topical, parenteral and/or oral administration, all of which are described herein. Parenteral
administration includes, without limitation, intravenous, intraperitoneal, subcutaneous and/or
intramuscular administration (e.g., skeletal muscle or cardiac muscle administration). In the
methods of this invention, a compound or composition of this invention may be administered
alone and/or simultaneously with one or more other compounds. In some embodiments, the
compounds may be administered sequentially, in any order. It will be appreciated that the
actual method and order of administration will vary according to, inter alia, the particular
preparation of compound(s) being utilized, and the particular formulation(s) of the one or
more other compounds being utilized. The optimal method and order of administration of the
compounds of the invention for a given set of conditions can be ascertained by those skilled
in the art using conventional techniques and in view of the information set out herein.
The term "administering" or "administered" also refers, without limitation, to oral,
sublingual, buccal, transnasal, transdermal, topical, rectal, intraperitoneal, intramuscular,
intravenous, intraarterial (intracoronary), intraventricular, intrathecal, and subcutaneous
routes. In accordance with good clinical practice, the instant compounds can be administered
at a dose that will produce effective beneficial effects without causing undue harmful or
untoward side effects, i.e., the benefits associated with administration outweigh the
detrimental effects.
Also as used herein, the terms "treat," "treating" or "treatment" refer to any type of
action that imparts a modulating effect, which, for example, can be a beneficial and/or
therapeutic effect, to a subject afflicted with a condition, disorder, disease or illness,
including, for example, improvement in the condition of the subject (e.g., in one or more
symptoms), delay in the progression of the disorder, disease or illness, delay of the onset of
the disease, disorder, or illness, and/or change in clinical parameters of the condition,
disorder, disease or illness, etc., as would be well known in the art.
As used herein, the terms "prevent," "preventing" or "prevention of (and
grammatical variations thereof) refer to prevention and/or delay of the onset and/or
progression of a disease, disorder and/or a clinical symptom(s) in a subject and/or a reduction
in the severity of the onset and/or progression of the disease, disorder and/or clinical
symptom(s) relative to what would occur in the absence of the methods of the invention. In
representative embodiments, the term "prevent," "preventing," or "prevention of (and
grammatical variations thereof) refer to prevention and/or delay of the onset and/or
progression of a metabolic disease in the subject, with or without other signs of clinical
disease. The prevention can be complete, e.g., the total absence of the disease, disorder
and/or clinical symptom(s). The prevention can also be partial, such that the occurrence of
the disease, disorder and/or clinical symptom(s) in the subject and/or the severity of onset
and/or the progression is less than what would occur in the absence of the present invention.
An "effective amount" or "therapeutically effective amount" refers to an amount of a
compound or composition of this invention that is sufficient to produce a desired effect,
which can be a therapeutic and/or beneficial effect. The effective amount will vary with the
age, general condition of the subject, the severity of the condition being treated, the particular
agent administered, the duration of the treatment, the nature of any concurrent treatment, the
pharmaceutically acceptable carrier used, and like factors within the knowledge and expertise
of those skilled in the art. As appropriate, an effective amount or therapeutically effective
amount in any individual case can be determined by one of ordinary skill in the art by
reference to the pertinent texts and literature and/or by using routine experimentation. (See,
for example, Remington, The Science and Practice of Pharmacy (latest edition)).
"15-deoxy 2 PGJ2-EA," "15dD12,14-PGJ-EA" or "15d-PGJ-EA" refer to 15-
deoxy A 2 ' -prostagladin J2-ethanolamide as set forth in formula (I):
"Prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent
compound of the above formulae, for example, by hydrolysis in blood. A thorough discussion
is provided in T. Higuchi and V. Stella, Prodrugs as Novel delivery Systems, Vol. 14 of the
A.C.S. Symposium Series and in Edward B. Roche, ed., Bioreversible Carriers in Drug
Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are
incorporated by reference herein. See also US Patent No. 6,680,299 Examples include a
prodrug that is metabolized in vivo by a subject to an active drug having an activity of active
compounds as described herein, wherein the prodrug is an ester of an alcohol or carboxylic
acid group, if such a group is present in the compound; an acetal or ketal of an alcohol group,
if such a group is present in the compound; an N-Mannich base or an imine of an amine
group, if such a group is present in the compound; or a Schiff base, oxime, acetal, enol ester,
oxazolidine, or thiazolidine of a carbonyl group, if such a group is present in the compound.
Particular prodrugs of the present invention include Prostaglandin D2 ethanolamide
(PGD -EA") as set forth in formula (II):
"Salt" or "pharmaceutically acceptable salt" as used herein refers to a salt that retains
the biological effectiveness of the free acids and bases of a specified compound and is not
biologically or otherwise undesirable. Examples of pharmaceutically acceptable salts include
sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates,
dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides,
acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates,
heptanoates, propionates, oxalates, malonates, succinates, sebacates, fumarates, maleates,
butyne-l,4-dioates, hexyne-l,6-dioates, benzoates, chlorobenzoates, methyl benzoates,
dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates,
xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-
hydroxybutyrates, glycollates, tartrates, methane-sulfonates, propanesulfonates, naphthalene-
1-sulfonates, naphthalene-2-sulfonates, and mandelates. In particular embodiments, the salt
is a hydrochloride, sulfite, benzoate, salicykate, cocoate, tallowate, undecylenate or
carboxylate salt.
Provided herein are compounds, compositions, and methods for treating and/or
preventing skin and/or oral disorders. In some embodiments, the skin and/or oral disorder is
a noncancerous or precancerous disorder. In some embodiments, a method of the present
invention is selectively toxic to cells having an increased level of ER stress compared to
normal cells of the same type.
Studies with 15d-PGJ2-EA and tumor cells determined that the selective death in
tumor cells was mediated by the induction of endoplasmic reticulum (ER) stress. In some
embodiments, a compound and/or composition of the present invention can
induce ER stress in cells and can push cells with moderate or greater levels of ER stress
beyond their death threshold. In contrast, normal cells may contain low endogenous ER
stress, and an equivalent amount of the compound and/or composition will not result in cell
death of the normal cells, thereby producing selective toxicity. Selectively targeting the
diseased cells may decrease the risk of developing adverse effects.
In some embodiments, a method of the present invention may treat and/or prevent a
skin and/or oral disorder that is associated with and/or mediated by increased ER stress. In
some embodiments, a method of the present invention may treat and/or prevent a skin and/or
oral disorder in which the skin and/or oral cells are exhibiting increased ER stress. In some
embodiments, the increased ER stress is during the growth cycle of cells (e.g., infected cells).
Cells treated by a method of the present invention may exhibit a level of ER stress that is at
least about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%,
150%, 200%, or more) greater than the level of ER stress in a normal, healthy cell of the
same type. The level of ER stress may be determined by the level of ER stress protein
expression in the cells.
The endoplasmic reticulum (ER) stress pathway has emerged as a novel therapeutic
target to selectively eliminate virus-containing cells. Numerous viruses such as the hepatitis
virus, the human immunodeficiency virus (HIV), herpesvirus and human papillomavirus
(HPV) rely on the ER stress pathway to process viral proteins, replicate, and survive. Cells
infected with HPV can have elevated levels of ER stress. HPV is a worldwide cause of
morbidity and mortality with clinical manifestations that include cervical cancer, anogenital
cancer, genital warts and cutaneous warts.
Cutaneous warts are common benign growths that occur in approximately 10% of
children and adolescents. Warts are contagious, recurrent, socially stigmatizing and can be
resistant to therapy. These lesions typically are removed using liquid nitrogen cryotherapy,
C0 2 laser vaporization, or topical chemotherapeutic approaches such as salicylic acid and
imiquimod. However, these therapeutic approaches can cause pain, permanent scarring, skin
necrosis, nerve injury and local inflammation due to the impact of the procedure/ agent on the
uninvolved skin. As such, therapeutic strategies are desired that target virus-infected cells
while causing minimal damage to uninfected cells. Our group discovered and synthesized the
novel agent, 15deoxy, A 2 ' prostaglandin-ethanolamide (also known as 15deoxy,
A1 ' prostamide J2 or 15dPMJ ) which exhibited targeted toxicity in skin tumor cells and
minimal toxicity in non-tumor skin cells due to the induction of ER stress.
Additionally, the ER is an intracellular organelle that is primarily responsible for
folding newly synthesized proteins. ER stress occurs when the protein-folding demand
exceeds the protein-folding capacity thereby causing misfolded or unfolded proteins to
accumulate. In response to ER stress, cells decrease global translation, increase synthesis of
protein-folding enzymes, and degrade misfolded or unfolded proteins to resolve the ER stress
and survive. However, when ER stress is too severe, the ER stress machinery becomes
overloaded and apoptotic death is initiated. Viral proteins are synthesized in large quantities
to facilitate replication, viral particle formation, and survival. This increased protein
processing demand activates the ER stress pathway. One strategy for novel therapeutic
development is to employ ER stress inducers to further elevate the level of ER stress, which
ultimately can initiate cell death in virus infected cells. ER stress can selectively eliminate
virus-infected cells because normal cells contain low endogenous ER stress levels that require
higher levels of the ER stress inducer to initiate death compared to virus infected cells (Fig.
1) . Since ER stress is elevated in HPV-infected but not uninfected cells 15dPMJ may cause
the ER stress machinery to be selectively overwhelmed in HPV-containing cells thereby
facilitating its elimination.
We have demonstrated that arachidonoyl-ethanolamide (AEA) was metabolized to the
novel Prostaglandin-ethanolamides (prostamide), 15dPMJ by cyclooxygenase-2 (COX-2)
(14-16). 15dPMJ2 activates the ER stress pathway and is selectively toxic to tumor cells (Fig.
2) .
Thus, methods of administration and use of the compounds and compositions
described herein are directed to the treatment and/or prevention of skin and/or oral disorders.
Accordingly, another embodiment of the present invention provides a method for
administering to a subject in need thereof a compound or pharmaceutical composition as
described herein for the prevention or treatment of skin disorders (including precancerous or
noncancerous skin disorders) or oral disorders. In some embodiments, the skin and/or oral
disorder may be a viral infection and/or caused by a viral infection. In some embodiments, a
method of the present invention may treat and/or prevent a viral infection in a subject without
cytotoxicity to cells that do not contain the virus (i.e., non-viral cells) or with reduced
cytotoxicity to non-viral cells. In some embodiments, a method of the present invention may
treat and/or prevent a skin and/or oral disorder in a subject without cytotoxicity to cells that
do not have an increased level of ER stress or with reduced cytotoxicity to cells that do not
have an increased level of ER stress. A method of the present invention may treat and/or
prevent a skin and/or oral disorder in a subject with reduced non-viral cell cytotoxicity and/or
reduced normal, healthy cell cytotoxicity compared to a different method for treating and/or
preventing the skin and/or oral disorder, such as, for example, one that does not administer a
compound and/or composition of the present invention.
In some embodiments, a method of the present invention may be cytotoxic to viral
cells and/or cells having an increased level of ER stress compared to normal, healthy cells.
The method may provide increased cytotoxicity to such cells compared to a different method
for treating and/or preventing the skin and/or oral disorder, such as, for example, one that
does not administer a compound and/or composition of the present invention. In some
embodiments, the cytotoxicity may be increased by at least about 10%, 15%, 20%, 25%,
30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%,
100%, 150% , or more compared to a different method for treating and/or preventing the skin
and/or oral disorder. Cytotoxicity may be determined using methods known to those of skill
in the art, such as, for example, a qualitative reading of hematoxylin & eosin (H&E) slides, a
lactate dehydrogenase (LDH) assay and/or a 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-
tetrazolium bromide (MTT) assay.
For administration, either the compound or pharmaceutical composition is understood
as being or comprising the active ingredient and capable of administration to a subject, and
thus, in some instances, the terms are interchangeable. Non-limiting methods of
administration include, but are not limited to oral, parenteral (e.g., subcutaneous,
intramuscular, intradermal, intraperitoneal, or intravenous), inhalation spray (nasal and oral),
topical (i.e., both skin and mucosal surfaces, including airway surfaces), transdermal, rectal,
nasal, sublingual, buccal, or implanted reservoir administration, etc. In one embodiment, a
composition of the present invention is administered topically or transdermally. In some
embodiments, a composition of the present invention is administered topically. In yet another
embodiment, a composition of the present invention is administered intraperitoneally.
The pharmaceutical compositions of the present invention may be suitably formulated
for administration by any means known in the art. Non-limiting examples of forms of
administration include, but are not limited to oral, parenteral (e.g., subcutaneous, intravenous,
intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic,
intralesional and intracranial injection or infusion techniques), inhalation spray (nasal and
oral), topical (i.e., both skin and mucosal surfaces, including airway surfaces), transdermal,
rectal, nasal, sublingual, buccal, or implanted reservoir administration, etc. In one
embodiment, a composition of the present invention is administered topically or
transdermally. For topical administration, suitable forms include, but are not limited to,
suitable transdermal delivery systems known in the art, such as patches, and for nasal
delivery, suitable forms include, but are not limited to, aerosol and nebulized delivery
systems known in the art.
In some embodiments, a pharmaceutical composition of the present invention may be
in the form suitable for topical administration. Non-limiting examples include, but are not
limited to, pharmaceutical compositions in the form of a topical solution, ointment, cream,
emulsion, a gel, a dispersion, a suspension, a foam, an aerosol, a droplet, an injectable form
and/or a coating in which the active component may be suspended or dissolved in one or
more carriers. A topical composition may be applied to body surfaces of a subject, including
skin, mucous membranes, scalp, hair and/or nails. Carriers for topical administration of the
compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum,
white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound,
emulsifying wax and water. Where the topical formulation is in the form of an ointment or
cream, suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate,
polysorbate 60, cetyl esters wax, cetearyl alcohol, 2 octyldodecanol, benzyl alcohol and
water.
Methods of formulating pharmaceutical compositions have been described in
numerous publications such as Pharmaceutical Dosage Forms: Tablets. Second Edition.
Revised and Expanded. Volumes 1-3, edited by Lieberman et al; Pharmaceutical Dosage
Forms: Parenteral Medications. Volumes 1-2, edited by Avis et al; and Pharmaceutical
Dosage Forms: Disperse Systems. Volumes 1-2, edited by Lieberman et al; published by
Marcel Dekker, Inc, the disclosure of each of which are herein incorporated by reference in
their entireties and for all purposes.
The pharmaceutical compositions are generally formulated as sterile, substantially
isotonic and in full compliance with all Good Manufacturing Practice (GMP) regulations of
the U.S. Food and Drug Administration.
According to embodiments of the present invention, precancerous conditions include,
but are not limited to, actinic keratosis, hypertrophic actinic keratosis, bowenoid actinic
keratosis and actinic cheilitis.
According to still other embodiments of the present invention, skin disorders include,
but are not limited to, skin cancer (basal and squamous cell carcinoma), acne, psoriasis,
warts, herepes, rosacea, seborrheic eczema, hives (allergic or idiopathic urticaria), cutaneous
candidiasis (fungi-mediated), carbuncles, cellulitis, impetigo, erysipelas, eczema, cancer
sores (virus-mediated), cold sores, ichthyosis vulgaris, dermatomyositis, acrodermatitis,
sebaceous cyst, keloid, lichen planus, corns, calluses, tinea versicolor, shingles (virus-
mediated), congenital erythropoietic porphyria, dermatitis, contact dermatitis, Darier's
disease, dystrophic epidermolysis bullosa, epidermolysis bullosa simplex, Hailey-hailey
disease, hidradenitis, suppurativa, hirsutism, hyperhidrosis, ichthyosis, keratosis pilaris,
melanoma, pemphigus vulgaris, scabies (mite-mediated), Sweet's syndrome, vitiligo,
pyoderma gangrenosum, and pityriasis lechenoides. "Psoriasis" as used herein can refer to a
chronic, relapsing/remitting, immune-mediated skin disease characterized by red, scaly
patches, papules, and plaques, which may itch. There are generally five main types of
psoriasis: plaque, guttate, inverse, pustular, and erythrodermic. Skin disorders also include
disorders associated with ER stress.
According to further embodiments of the present invention, oral disorders include, but
are not limited to, cold sores (virus-mediated), canker sores (virus-mediated), thrush (fungi-
mediated), leukoplakia, dry mouth, stomatitis, glossitis, oral lichen planus, oral cancer,
salivary gland stones, salivary gland tumors, pulpitis, dental abscess, gingivitis, periodontitis,
receding gums, gingival hyperplasia and dry socket. Oral disorders also include disorders
associated with ER stress.
In some embodiments, a method of the present invention may prevent and/or reduce
the appearance and/or size of a wart. Example warts include, but are not limited to, common
warts (verruca vulgaris), flat warts (verruca plana), filiform warts (verruca acuminate),
mosaic warts, periungal warts, and/or plantar warts. In some embodiments, the wart may be
induced and/or caused by a papillomavirus, such as a human papillomavirus.
A method of the present invention may reduce the appearance and/or size of a wart by
at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%,
75%, 80%, 85%, 90%, 95%, 97% or 100% compared to the appearance and/or size of a
benign lesion prior to administering of a compound and/or composition of the present
invention. The appearance of the wart may be evaluated visually, such as, but not limited to,
by the subject and/or a physician. The size of the wart may be determined using methods
known to those of skill in the art.
In some embodiments, the subject may see a reduction in the size and/or appearance
of a wart within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or more day(s) and/or week(s). In some
embodiments, the method may reduce the size and/or appearance of a wart in the skin of the
subject with 12 weeks or less, in some embodiments, within 8 weeks or less, and in further
embodiments, within 4 weeks or less.
A method of the present invention may reduce the number of warts by at least about
5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 97% or 100% compared to the number of warts prior to administering of a
compound and/or composition of the present invention. The number of warts may be
evaluated visually, such as, but not limited to, by the subject and/or a physician. The number
of warts may be determined using methods known to those of skill in the art.
A method of the present invention may decrease the rate of recurrence of a wart in a
subject by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,
65%, 70%, 75%, 80%, 85%, 90%, 95%, 97% or 100% compared to the rate of recurrence of
the same type of wart in the absence of administering of a compound and/or composition of
the present invention. The rate of recurrence may be determined using methods known to
those of skill in the art. For example, after a treatment and/or removal of a wart, the number
of warts may be visually determined after a given period of time to determine the rate of
recurrence.
In some embodiments, a method of the present invention may prevent and/or reduce
the appearance and/or size of a precancerous or noncancerous lesion, such as, for example, a
papular lesion, psoriasis, and/or macular lesion. In some embodiments, the precancerous or
noncancerous lesion may be caused by and/or induced by a viral infection. In some
embodiments, the precancerous or noncancerous lesion is a skin lesion. In some
embodiments, the precancerous or noncancerous lesion may be induced and/or caused by a
papillomavirus, such as a human papillomavirus. In some embodiments, at least a portion of
or all of the cells in the precancerous or noncancerous lesion have an increased level of ER
stress.
A method of the present invention may reduce the appearance and/or size of a
precancerous or noncancerous lesion by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%,
40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97% or more compared
to the appearance and/or size of the precancerous or noncancerous lesion prior to
administering of a compound and/or composition of the present invention. The appearance of
the precancerous or noncancerous lesion may be evaluated visually, such as, but not limited
to, by the subject and/or a physician. The size of the precancerous or noncancerous lesion
may be determined using methods known to those of skill in the art.
A method of the present invention may reduce the number of precancerous or
noncancerous lesions by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%,
50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97% or 100% compared to the
number of precancerous or noncancerous lesions prior to administering of a compound and/or
composition of the present invention. The number of precancerous or noncancerous lesions
may be evaluated visually, such as, but not limited to, by the subject and/or a physician. The
number of precancerous or noncancerous lesions may be determined using methods known to
those of skill in the art.
A method of the present invention may decrease the rate of recurrence of a
precancerous or noncancerous lesion in a subject by at least about 5%, 10%, 15%, 20%>, 25%,
30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97% or
10 0% compared to the rate of recurrence of the same type of precancerous or noncancerous
lesion in the absence of administering of a compound and/or composition of the present
invention. The rate of recurrence may be determined using methods known to those of skill
in the art. For example, after a treatment and/or removal of a precancerous or noncancerous
lesion, the number of precancerous or noncancerous lesions may be visually determined after
a given period of time to determine the rate of recurrence.
In some embodiments, the subject may be administered a second therapeutic agent
and/or therapy (such as, e.g., antineoplastic chemotherapy or radiotherapy) prior to, at the
same time, or after receiving a compound and/or composition of the present invention. The
antineoplastic chemotherapy can be one or more of: folate antagonists, including
methotrexate and pemetrexed; purine antagonists, including cladribine, clofarabine,
fludarabine, 6-mercaptopurine, nelarabine, pentostatin; pyrimidine antagonists, including
capecitabine, cytarabine, 5-fluorouracil, gemcitabine, hydroxyurea; biologic response
modifiers, including interferon-alfa; bleomycin; DNA alkylating agents, including
nitrosureas, carmustine, lomustine; DNA cross-linking drugs and alkylating agents, including
bendamustine, chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine (nitrogen
mustard), melphalan, dacarbazine, temozolomide, procarbazine; asparaginase; antibiotics,
including mitomycin; platinum complexes, including carboplatin, cisplatin, oxaliplatin;
proteosome inhibitors, including bortezomib; spindle poisons, such as the taxanes (including
docetaxel, paclitaxel, nab-paclitaxel (Abraxane.RTM.)) and the vincas (including vinblastine,
vincristine, vinorelbine); topoisomerase inhibitors, such as the anthracyclines (including
daunorubicin, daunomycin, doxorubicin, epirubicin), the camptothecines, (including
irinotecan, topotecan), the podophyllotoxins (including etoposide, teniposide and
mitoxantrone); tyrosine kinase inhibitors, (including erlotinib (Tarceva), gefitinib, imatinib,
lapatinib, pazopanib, sorafenib, sunitinib); and ifosfamide.
It should also be understood that a specific dosage and treatment regimen for any
particular patient will depend upon a variety of factors, including but not limited to, the age,
body weight, general health, gender, diet, time of administration, rate of excretion, drug
combination, and the judgment of the treating physician and the severity of the particular
disease being treated.
In some embodiments, a compound and/or composition of the present invention may
be administered (e.g., topically administered) to a subject using any method known to those
of skill in the art. In some embodiments, the compound and/or composition may be
administered (e.g., topically applied) to the subject at least 1, 2, 3, or more times per day. In
some embodiments, the compound and/or composition may be administered (e.g., topically
applied) to the subject at least 1, 2, 3, 4, 5, 6, 7, 8, or more times per week and/or month. In
some embodiments, the compound and/or composition may be administered to the subject
once daily, twice daily, every other day, every third day, once per week, or twice per week.
In some embodiments, the compound and/or composition may be administered at least once
daily for an extended period of time (e.g., a week, month, 2 months, etc.) and/or until the skin
and/or oral disorder has been treated and/or prevented. In some embodiments, the compound
and/or composition may be applied on an as needed basis.
Subjects suitable to be treated according to the present invention include, but are not
limited to, avian and mammalian subjects, and are preferably mammalian. Mammals of the
present invention include, but are not limited to, canines, felines, bovines, caprines, equines,
ovines, porcines, rodents (e.g. rats and mice), lagomorphs, primates, humans, and the like,
and mammals in utero. Any mammalian subject in need of being treated according to the
present invention is suitable. Human subjects are preferred. The human subjects may be
male or female and may be of any race or ethnicity, including, but not limited to, Caucasian,
African-American, African, Asian, Hispanic, Indian, etc. The subjects may be of any age,
including newborn, neonate, infant, child, adolescent, adult, and geriatric.
Illustrative avians according to the present invention include chickens, ducks, turkeys,
geese, quail, pheasant, ratites (e.g., ostrich) and domesticated birds (e.g., parrots and
canaries), and birds in ovo.
The present invention is primarily concerned with the treatment of human subjects,
but the invention can also be carried out on animal subjects, particularly mammalian subjects
such as mice, rats, dogs, cats, livestock and horses for veterinary purposes, drug screening,
and/or drug development purposes.
The compounds of the present invention may be formulated as the sole
pharmaceutically active ingredient in a composition of the present invention or may be
combined with other active ingredients.
A composition of the present invention may contain one or more compounds of the
present invention. In some embodiments, the compounds may be formulated into suitable
pharmaceutical preparations such as solutions, suspensions, tablets, dispersible tablets, pills,
capsules, powders, sustained release formulations or elixirs, for oral administration or in
sterile solutions or suspensions for parenteral administration, as well as transdermal patch
preparation and dry powder inhalers. In one embodiment, the compounds described above are
formulated into pharmaceutical compositions using techniques and procedures well known in
the art (see, e.g., Ansel, Introduction to Pharmaceutical Dosage Forms, Fourth Edition 1985,
126).
In the compositions, effective concentrations of one or more compounds or
pharmaceutically acceptable derivatives thereof may be (are) mixed with a suitable
pharmaceutical carrier. The compounds may be derivatized as the corresponding salts, esters,
enol ethers or esters, acetals, ketals, orthoesters, hemiacetals, hemiketals, acids, bases,
solvates, hydrates or prodrugs prior to formulation, as described above. The concentrations of
the compounds in the compositions may be effective for delivery of an amount, upon
administration, that treats, prevents, and/or ameliorates one or more of the symptoms of
diseases or disorders associated with a skin disorder and/or oral disorder.
In one embodiment, the compositions are formulated for single dosage administration.
To formulate a composition, the weight fraction of a compound of the present invention is
dissolved, suspended, dispersed or otherwise mixed in a selected carrier at an effective
concentration such that the treated condition is relieved, prevented, or one or more symptoms
may be ameliorated.
The active compound may be included in the pharmaceutically acceptable carrier in
an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side
effects on the subject treated. The therapeutically effective concentration may be determined
empirically by testing the compounds in in vitro and in vivo systems described herein and in
U.S. Pat. No. 5,952,366 to Pandey et al. (1999) and then extrapolated therefrom for dosages
for humans.
The concentration of active compound in the pharmaceutical composition may depend
on absorption, inactivation and excretion rates of the active compound, the physicochemical
characteristics of the compound, the dosage schedule, and/or the amount administered as well
as other factors known to those of skill in the art. For example, the amount that is delivered
may be sufficient to ameliorate one or more of the symptoms of a skin disorder and/or oral
disorder as described herein.
In one embodiment, a therapeutically effective dosage should produce a serum
concentration of the active ingredient of from about 0.1 ng/ml to about 50-100 ug/ml. In one
embodiment, a therapeutically effective dosage is from 0.001, 0.01 or 0.1 to 10, 100 or 1000
mg of active compound per kilogram of body weight per day. Pharmaceutical dosage unit
forms may be prepared to provide from about 0.01 mg, 0.1 mg or 1 mg to about 500 mg,
1000 mg or 2000 mg, and in one embodiment from about 10 mg to about 500 mg of the
active ingredient or a combination of essential ingredients per dosage unit form.
The active ingredient may be administered at once, or may be divided into a number
of smaller doses to be administered at intervals of time. It is understood that the precise
dosage and duration of treatment is a function of the disease being treated and may be
determined empirically using known testing protocols or by extrapolation from in vivo or in
vitro test data. It is to be noted that concentrations and dosage values may also vary with the
severity of the condition to be alleviated. It is to be further understood that for any particular
subject, specific dosage regimens should be adjusted over time according to the individual
need and the professional judgment of the person administering or supervising the
administration of the compositions, and that the concentration ranges set forth herein are
exemplary only and are not intended to limit the scope or practice of the claimed
compositions.
In instances in which the compounds exhibit insufficient solubility, methods for
solubilizing compounds may be used. Such methods are known to those of skill in this art,
and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO),
using surfactants, such as TWEEN™, or dissolution in aqueous sodium bicarbonate.
Derivatives of the compounds, such as prodrugs of the compounds may also be used in
formulating effective pharmaceutical compositions.
Upon mixing or addition of the compound(s), the resulting mixture may be a solution,
suspension, emulsion, gel, or the like. The form of the resulting mixture depends upon a
number of factors, including the intended mode of administration and the solubility of the
compound in the selected carrier or vehicle. The effective concentration may be sufficient for
ameliorating the symptoms of the disease, disorder or condition treated and may be
empirically determined.
The pharmaceutical compositions may be provided for administration to humans
and/or animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile
parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water
emulsions containing suitable quantities of the compounds or pharmaceutically acceptable
derivatives thereof. The pharmaceutically therapeutically active compounds and derivatives
thereof are, in one embodiment, formulated and administered in unit-dosage forms or
multiple-dosage forms. Unit-dose forms as used herein refers to physically discrete units
suitable for human and animal subjects and packaged individually as is known in the art.
Each unit-dose contains a predetermined quantity of the therapeutically active compound
sufficient to produce the desired therapeutic effect, in association with the required
pharmaceutical carrier, vehicle or diluent. Examples of unit-dose forms include ampoules and
syringes and individually packaged tablets or capsules. Unit-dose forms may be administered
in fractions or multiples thereof. A multiple-dose form is a plurality of identical unit-dosage
forms packaged in a single container to be administered in segregated unit-dose form.
Examples of multiple-dose forms include vials, bottles of tablets or capsules or bottles of
pints or gallons. Hence, multiple dose form is a multiple of unit-doses which are not
segregated in packaging.
Liquid pharmaceutically administrable compositions may, for example, be prepared
by dissolving, dispersing, or otherwise mixing an active compound as defined above and
optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous
dextrose, glycerol, glycols, ethanol, and the like, to thereby form a solution or suspension. If
desired, the pharmaceutical composition to be administered may also contain minor amounts
of nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing
agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrin
derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate,
and other such agents.
Actual methods of preparing such dosage forms are known, or will be apparent, to
those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack
Publishing Company, Easton, Pa., 15th Edition, 1975.
Dosage forms or compositions containing active ingredient in the range of 0.005% to
100% with the balance made up from non-toxic carrier may be prepared. Methods for
preparation of these compositions are known to those skilled in the art. The contemplated
compositions may contain 0.001%-100% active ingredient by weight of the composition, in
one embodiment 0.1-95% by weight of the composition, in another embodiment 75-85% by
weight of the composition, and in another embodiment 0.5%-50% by weight of the
composition.
In some embodiments, a composition of the present invention may be suitable for oral
administration. Oral pharmaceutical dosage forms are either solid, gel or liquid. The solid
dosage forms are tablets, capsules, granules, and bulk powders. Types of oral tablets include
compressed, chewable lozenges and tablets which may be enteric-coated, sugar-coated or
film-coated. Capsules may be hard or soft gelatin capsules, while granules and powders may
be provided in non-effervescent or effervescent form with the combination of other
ingredients known to those skilled in the art.
In certain embodiments, the formulations are solid dosage forms, in one embodiment,
capsules or tablets. The tablets, pills, capsules, troches and the like may contain one or more
of the following ingredients, or compounds of a similar nature: a binder; a lubricant; a
diluent; a glidant; a disintegrating agent; a coloring agent; a sweetening agent; a flavoring
agent; a wetting agent; an emetic coating; and a film coating. Examples of binders include
microcrystalline cellulose, gum tragacanth, glucose solution, acacia mucilage, gelatin
solution, molasses, polvinylpyrrolidine, povidone, crospovidones, sucrose and starch paste.
Lubricants include talc, starch, magnesium or calcium stearate, lycopodium and stearic acid.
Diluents include, for example, lactose, sucrose, starch, kaolin, salt, mannitol and dicalcium
phosphate. Glidants include, but are not limited to, colloidal silicon dioxide. Disintegrating
agents include crosscarmellose sodium, sodium starch glycolate, alginic acid, corn starch,
potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose. Coloring agents
include, for example, any of the approved certified water soluble FD and C dyes, mixtures
thereof; and water insoluble FD and C dyes suspended on alumina hydrate. Sweetening
agents include sucrose, lactose, mannitol and artificial sweetening agents such as saccharin,
and any number of spray dried flavors. Flavoring agents include natural flavors extracted
from plants such as fruits and synthetic blends of compounds which produce a pleasant
sensation, such as, but not limited to peppermint and methyl salicylate. Wetting agents
include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate
and polyoxyethylene laural ether. Emetic-coatings include fatty acids, fats, waxes, shellac,
ammoniated shellac and cellulose acetate phthalates. Film coatings include
hydroxyethylcellulose, gellan gum, sodium carboxymethylcellulose, polyethylene glycol
4000 and cellulose acetate phthalate.
The compound, or pharmaceutically acceptable derivative thereof, may be provided in
a composition that protects it from the acidic environment of the stomach. For example, the
composition may be formulated in an enteric coating that maintains its integrity in the
stomach and releases the active compound in the intestine. The composition may also be
formulated in combination with an antacid or other such ingredient. When the dosage unit
form is a capsule, it may contain, in addition to material of the above type, a liquid carrier
such as a fatty oil. In addition, dosage unit forms may contain various other materials which
modify the physical form of the dosage unit, for example, coatings of sugar and other enteric
agents. The compounds may be administered as a component of an elixir, suspension, syrup,
wafer, sprinkle, chewing gum or the like. A syrup may contain, in addition to the active
compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and
flavors.
The active materials may also be mixed with other active materials which do not
impair the desired action, or with materials that supplement the desired action, such as
antacids, H2 blockers, and diuretics. The active ingredient is a compound or pharmaceutically
acceptable derivative thereof as described herein. Higher concentrations, up to about 98% by
weight of the active ingredient may be included.
In all embodiments, tablets and capsules formulations may be coated as known by
those of skill in the art in order to modify or sustain dissolution of the active ingredient. Thus,
for example, they may be coated with a conventional enterically digestible coating, such as
phenylsalicylate, waxes and cellulose acetate phthalate.
Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions
and/or suspensions reconstituted from non-effervescent granules and effervescent
preparations reconstituted from effervescent granules. Aqueous solutions include, for
example, elixirs and syrups. Emulsions are either oil-in-water or water-in-oil.
Elixirs are clear, sweetened, hydroalcoholic preparations. Pharmaceutically acceptable
carriers used in elixirs include solvents. Syrups are concentrated aqueous solutions of a sugar,
for example, sucrose, and may contain a preservative. An emulsion is a two-phase system in
which one liquid is dispersed in the form of small globules throughout another liquid.
Pharmaceutically acceptable carriers used in emulsions are non-aqueous liquids, emulsifying
agents and preservatives. Suspensions use pharmaceutically acceptable suspending agents
and preservatives. Pharmaceutically acceptable substances used in non-effervescent granules,
to be reconstituted into a liquid oral dosage form, include diluents, sweeteners and wefting
agents. Pharmaceutically acceptable substances used in effervescent granules, to be
reconstituted into a liquid oral dosage form, include organic acids and a source of carbon
dioxide. Coloring and flavoring agents are used in all of the above dosage forms. Solvents
include glycerin, sorbitol, ethyl alcohol and syrup. Examples of preservatives include
glycerin, methyl and propylparaben, benzoic acid, sodium benzoate and alcohol. Examples of
non-aqueous liquids utilized in emulsions include mineral oil and cottonseed oil. Examples of
emulsifying agents include gelatin, acacia, tragacanth, bentonite, and surfactants such as
polyoxyethylene sorbitan monooleate. Suspending agents include sodium
carboxymethylcellulose, pectin, tragacanth, xanthan gum, Veegum and acacia. Sweetening
agents include sucrose, syrups, glycerin and artificial sweetening agents such as saccharin.
Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene
glycol monolaurate and polyoxyethylene lauryl ether. Organic acids include citric and tartaric
acid. Sources of carbon dioxide include sodium bicarbonate and sodium carbonate. Coloring
agents include any of the approved certified water soluble FD and C dyes, and mixtures
thereof. Flavoring agents include natural flavors extracted from plants such fruits, and
synthetic blends of compounds which produce a pleasant taste sensation. For a solid dosage
form, the solution or suspension, in for example propylene carbonate, vegetable oils or
triglycerides, is in one embodiment encapsulated in a gelatin capsule. Such solutions, and the
preparation and encapsulation thereof, are disclosed in U.S. Pat. Nos. 4,328,245; 4,409,239;
and 4,410,545. For a liquid dosage form, the solution, e.g., for example, in a polyethylene
glycol, may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid
carrier, e.g., water, to be easily measured for administration.
Alternatively, liquid or semi-solid oral formulations may be prepared by dissolving or
dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene
glycol esters (e.g., propylene carbonate) and other such carriers, and encapsulating these
solutions or suspensions in hard or soft gelatin capsule shells. Other useful formulations
include those set forth in U.S. Pat. Nos. RE28,819 and 4,358,603. Briefly, such formulations
include, but are not limited to, those containing a compound provided herein, a dialkylated
mono- or poly-alkylene glycol, including, but not limited to, 1,2-dimethoxymethane,
diglyme, triglyme, tetraglyme, polyethylene glycol-350-dimethyl ether, polyethylene glycol-
550-dimethyl ether, polyethylene glycol-750-dimethyl ether wherein 350, 550 and 750 refer
to the approximate average molecular weight of the polyethylene glycol, and one or more
antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA),
propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin,
ascorbic acid, malic acid, sorbitol, phosphoric acid, thiodipropionic acid and its esters, and
dithiocarbamates .
Other formulations include, but are not limited to, aqueous alcoholic solutions
including a pharmaceutically acceptable acetal. Alcohols used in these formulations are any
pharmaceutically acceptable water-miscible solvents having one or more hydroxyl groups,
including, but not limited to, propylene glycol and ethanol. Acetals include, but are not
limited to, di(loweralkyl) acetals of loweralkyl aldehydes such as acetaldehyde diethyl acetal.
Parenteral administration, in one embodiment characterized by injection, either
subcutaneously, intramuscularly or intravenously is also contemplated herein. Injectables
may be prepared in conventional forms, either as liquid solutions or suspensions, solid forms
suitable for solution or suspension in liquid prior to injection, or as emulsions. The
injectables, solutions and emulsions also contain one or more excipients. Suitable excipients
are, for example, water, saline, dextrose, glycerol or ethanol. In addition, if desired, the
pharmaceutical compositions to be administered may also contain minor amounts of non¬
toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents,
stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate,
sorbitan monolaurate, triethanolamine oleate and cyclodextrins.
Implantation of a slow-release or sustained-release system, such that a constant level
of dosage is maintained (see, e.g., U.S. Pat. No. 3,710,795) is also contemplated herein.
Briefly, a compound provided herein is dispersed in a solid inner matrix, e.g.,
polymethylmethacrylate, polybutylmethacrylate, plasticized or unplasticized
polyvinylchloride, plasticized nylon, plasticized polyethyleneterephthalate, natural rubber,
polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinylacetate
copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers,
hydrophilic polymers such as hydrogels of esters of acrylic and methacrylic acid, collagen,
cross-linked polyvinylalcohol and cross-linked partially hydrolyzed polyvinyl acetate, that is
surrounded by an outer polymeric membrane, e.g., polyethylene, polypropylene,
ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinylacetate
copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated
polyethylene, polyvinylchloride, vinylchloride copolymers with vinyl acetate, vinylidene
chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber
epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl
alcohol terpolymer, and ethylene/vinyloxyethanol copolymer, that is insoluble in body fluids.
The compound diffuses through the outer polymeric membrane in a release rate controlling
step. The percentage of active compound contained in such parenteral compositions is highly
dependent on the specific nature thereof, as well as the activity of the compound and the
needs of the subject.
Parenteral administration of the compositions includes intravenous, subcutaneous and
intramuscular administrations. Preparations for parenteral administration include sterile
solutions ready for injection, sterile dry soluble products, such as lyophilized powders, ready
to be combined with a solvent just prior to use, including hypodermic tablets, sterile
suspensions ready for injection, sterile dry insoluble products ready to be combined with a
vehicle just prior to use and sterile emulsions. The solutions may be either aqueous or
nonaqueous.
If administered intravenously, suitable carriers include physiological saline or
phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents,
such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
Pharmaceutically acceptable carriers used in parenteral preparations include aqueous
vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants,
local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or
chelating agents and other pharmaceutically acceptable substances.
Examples of aqueous vehicles include Sodium Chloride Injection, Ringers Injection,
Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection.
Nonaqueous parenteral vehicles include fixed oils of vegetable origin, cottonseed oil, corn
oil, sesame oil and peanut oil. Antimicrobial agents in bacteriostatic or fungistatic
concentrations must be added to parenteral preparations packaged in multiple-dose containers
which include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and
propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium
chloride. Isotonic agents include sodium chloride and dextrose. Buffers include phosphate
and citrate. Antioxidants include sodium bisulfate. Local anesthetics include procaine
hydrochloride. Suspending and dispersing agents include sodium carboxymethylcelluose,
xanthan gum, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifying agents
include Polysorbate 80 (TWEEN™ 80). A sequestering or chelating agent of metal ions
includes EDTA. Pharmaceutical carriers also include ethyl alcohol, polyethylene glycol and
propylene glycol for water miscible vehicles; and sodium hydroxide, hydrochloric acid, citric
acid or lactic acid for pH adjustment.
The concentration of the pharmaceutically active compound is adjusted so that an
injection provides an effective amount to produce the desired pharmacological effect. The
exact dose depends on the age, weight and condition of the subject or animal as is known in
the art.
The unit-dose parenteral preparations may be packaged in an ampoule, a vial or a
syringe with a needle. All preparations for parenteral administration must be sterile, as is
known and practiced in the art.
Illustratively, intravenous or intraarterial infusion of a sterile aqueous solution
containing an active compound is an effective mode of administration. Another embodiment
is a sterile aqueous or oily solution or suspension containing an active material injected as
necessary to produce the desired pharmacological effect.
Injectables are designed for local and systemic administration. In one embodiment, a
therapeutically effective dosage is formulated to contain a concentration of at least about
0.1% w/w up to about 90% w/w or more, in certain embodiments more than 1% w/w of the
active compound to the treated tissue(s).
The compound may be suspended in micronized or other suitable form or may be
derivatized to produce a more soluble active product or to produce a prodrug. The form of the
resulting mixture depends upon a number of factors, including the intended mode of
administration and the solubility of the compound in the selected carrier or vehicle. The
effective concentration is sufficient for ameliorating the symptoms of the condition and may
be empirically determined.
Lyophilized powders, which can be reconstituted for administration as solutions,
emulsions and other mixtures, may also be used to carry out the present invention. They may
also be reconstituted and formulated as solids or gels.
The sterile, lyophilized powder is prepared by dissolving a compound provided
herein, or a pharmaceutically acceptable derivative thereof, in a suitable solvent. The solvent
may contain an excipient which improves the stability or other pharmacological component
of the powder or reconstituted solution, prepared from the powder. Excipients that may be
used include, but are not limited to, dextrose, sorbital, fructose, corn syrup, xylitol, glycerin,
glucose, sucrose or other suitable agent. The solvent may also contain a buffer, such as
citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art
at, in one embodiment, about neutral pH. Subsequent sterile filtration of the solution followed
by lyophilization under standard conditions known to those of skill in the art provides the
desired formulation. In one embodiment, the resulting solution will be apportioned into vials
for lyophilization. Each vial will contain a single dosage or multiple dosages of the
compound. The lyophilized powder can be stored under appropriate conditions, such as at
about 4 °C to room temperature.
Reconstitution of this lyophilized powder with water for injection provides a
formulation for use in parenteral administration. For reconstitution, the lyophilized powder is
added to sterile water or other suitable carrier. The precise amount depends upon the selected
compound. Such amount can be empirically determined.
Topical mixtures may be prepared as described for the local and systemic
administration. The resulting mixture may be a solution, suspension, emulsions or the like
and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions,
suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages,
dermal patches or any other formulations suitable for topical administration.
The compounds or pharmaceutically acceptable derivatives thereof may be
formulated as aerosols for topical application, such as by inhalation (see, e.g., U.S. Pat. Nos.
4,044,126; 4,414,209; and 4,364,923, which describe aerosols for delivery of a steroid useful
for treatment of inflammatory diseases, particularly asthma). These formulations for
administration to the respiratory tract may be in the form of an aerosol or solution for a
nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert
carrier such as lactose. In such a case, the particles of the formulation will, in one
embodiment, have diameters of less than 50 microns, in one embodiment less than 10
microns.
The compounds may be formulated for local or topical application, such as for topical
application to the skin and mucous membranes, such as in the eye, in the form of gels,
creams, and lotions and for application to the eye or for intracisternal or intraspinal
application. Topical administration is contemplated for transdermal delivery and also for
administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the active
compound alone or in combination with other pharmaceutically acceptable excipients may be
administered. These solutions, particularly those intended for ophthalmic use, may be
formulated as 0.01% -10% isotonic solutions, pH about 5-7, with appropriate salts.
Other routes of administration, such as transdermal patches, including iontophoretic
and electrophoretic devices, and rectal administration, are also contemplated herein.
Transdermal patches, including iontophoretic and electrophoretic devices, are well
known to those of skill in the art. For example, such patches are disclosed in U.S. Pat. Nos.
6,267,983; 6,261,595; 6,256,533; 6,167,301; 6,024,975; 6,010715; 5,985,317; 5,983,134;
5,948,433 and 5,860,957.
For example, pharmaceutical dosage forms for rectal administration are rectal
suppositories, capsules and tablets for systemic effect. Rectal suppositories as used herein
mean solid bodies for insertion into the rectum which melt or soften at body temperature
releasing one or more pharmacologically or therapeutically active ingredients.
Pharmaceutically acceptable substances utilized in rectal suppositories are bases or vehicles
and agents to raise the melting point. Examples of bases include cocoa butter (theobroma oil),
glycerin-gelatin, carbowax (polyoxyethylene glycol) and appropriate mixtures of mono-, di-
and triglycerides of fatty acids. Combinations of the various bases may be used. Agents to
raise the melting point of suppositories include spermaceti and wax. Rectal suppositories may
be prepared either by the compressed method or by molding. The weight of a rectal
suppository, in one embodiment, is about 2 to 3 gm.
Tablets and capsules for rectal administration are manufactured using the same
pharmaceutically acceptable substance and by the same methods as for formulations for oral
administration.
The compounds provided herein, or pharmaceutically acceptable derivatives thereof,
may also be formulated to be targeted to a particular tissue, receptor, infecting agent or other
area of the body of the subject to be treated. Many such targeting methods are well known to
those of skill in the art. All such targeting methods are contemplated herein for use in the
instant compositions. For non-limiting examples of targeting methods, see, e.g., U.S. Pat.
Nos. 6,316,652; 6,274,552; 6,271,359; 6,253,872; 6,139,865; 6,131,570; 6,120,751;
6,071,495; 6,060,082; 6,048,736; 6,039,975; 6,004,534; 5,985,307; 5,972,366; 5,900,252;
5,840,674; 5,759,542 and 5,709,874.
In one embodiment, liposomal suspensions, including tissue-targeted liposomes, such
as tumor-targeted liposomes, may also be suitable as pharmaceutically acceptable carriers.
These may be prepared according to methods known to those skilled in the art. For example,
liposome formulations may be prepared as described in U.S. Pat. No. 4,522,81 1. Briefly,
liposomes such as multilamellar vesicles (MLV's) may be formed by drying down egg
phosphatidyl choline and brain phosphatidyl serine (7:3 molar ratio) on the inside of a flask.
A solution of a compound provided herein in phosphate buffered saline lacking divalent
cations (PBS) is added and the flask shaken until the lipid film is dispersed. The resulting
vesicles are washed to remove unencapsulated compound, pelleted by centrifugation, and
then resuspended in PBS.
In another embodiment, the disclosed compounds may be targeted to specific target
tissues or target compositions using ligands specific for the target tissue or target
composition, for example, using ligands or ligand-receptor pairs such as antibodies and
antigens. Antibodies against tumor antigens and against pathogens are known. For example,
antibodies and antibody fragments which specifically bind markers produced by or associated
with tumors or infectious lesions, including viral, bacterial, fungal and parasitic infections,
and antigens and products associated with such microorganisms have been disclosed, inter
alia, in Hansen et al., U.S. Pat. No. 3,927,193 and Goldenberg, U.S. Pat. Nos. 4,331,647;
4,348,376; 4,361,544; 4,468,457; 4,444,744; 4,818,709 and 4,624,846. Antibodies against an
antigen, e.g., a gastrointestinal, lung, breast, prostate, ovarian, testicular, brain or lymphatic
tumor, a sarcoma or a melanoma, may be used.
A wide variety of monoclonal antibodies against infectious disease agents have been
developed, and are summarized in a review by Polin, in Eur. J . Clin. Microbiol., 3(5): 387-
398 (1984), showing ready availability. These include monoclonal antibodies (MAbs) against
pathogens and their antigens such as the following: Anti-bacterial Mabs such as those against
Streptococcus agalactiae, Legionella pneumophilia, Streptococcus pyogenes, Esherichia coli,
Neisseria gonorrhosae, Neisseria meningitidis, Pneumococcus, Hemophilis influenzae B,
Treponema pallidum, Lyme disease, spirochetes, Pseudomonas aeruginosa, Mycobacterium
leprae, Brucella abortus, Mycobacterium tuberculosis, Tetanus toxin, Anti-protozoan Mabs
such as those against Plasmodium falciparum, Plasmodium vivax, Toxoplasma gondii,
Trypanosoma rangeli, Trypanosoma cruzi, Trypanosoma rhodesiensei, Trypanosoma brucei,
Schistosoma mansoni, Schistosoma japanicum, Mesocestoides corti, Emeria tenella,
Onchocerca volvulus, Leishmania tropica, Trichinella spiralis, Theileria parva, Taenia
hydatigena, Taenia ovis, Taenia saginata, Anti-viral MAbs such as those against HIV-1, -2,
and -3, Hepatitis A, B, C, D, Rabies virus, Influenza virus, Cytomegalovirus, Herpes simplex
I and II, Human serum parvo-like virus, Respiratory syncytial virus, Varicella-Zoster virus,
Hepatitis B virus, Measles virus, Adenovirus, Human T-cell leukemia viruses, Epstein-Barr
virus, Mumps virus, Sindbis virus, Mouse mammary tumor virus, Feline leukemia virus,
Lymphocytic choriomeningitis virus, Wart virus, Blue tongue virus, Sendai virus, Reo virus,
Polio virus, Dengue virus, Rubella virus, Murine leukemia virus, Antimycoplasmal MAbs
such as those against Acholeplasma laidlawii, Mycoplasma arthritidis, M . hyorhinis, M .
orale, M . arginini, M .pneumonia; etc.
Suitable MAbs have been developed against most of the micro-organisms (bacteria,
viruses, protozoa, other parasites) responsible for the majority of infections in humans, and
many have been used previously for in vitro diagnostic purposes. These antibodies, and
newer MAbs that can be generated by conventional methods, may be appropriate for use as
target agents with the compounds provided herein.
It should be noted that mixtures of antibodies and immunoglobulin classes may be
used, as may hybrid antibodies. Multispecific, including bispecific and hybrid, antibodies and
antibody fragments may be used in the methods of the present invention for detecting and
treating target tissue and may comprise at least two different substantially monospecific
antibodies or antibody fragments, wherein at least two of the antibodies or antibody
fragments specifically bind to at least two different antigens produced or associated with the
targeted lesion or at least two different epitopes or molecules of a marker substance produced
or associated with the target tissue. Multispecific antibodies and antibody fragments with
dual specificities can be prepared analogously to the anti-tumor marker hybrids disclosed in
U.S. Pat. No. 4,361,544. Other techniques for preparing hybrid antibodies are disclosed in,
e.g., U.S. Pat. Nos. 4,474,893 and 4,479,895, and in Milstein et al, Immunol. Today 5 : 299
(1984).
Antibody fragments useful in the present invention include F(ab')2, F(ab)2, Fab', Fab,
Fv and the like including hybrid fragments. In some embodiments, fragments are Fab',
F(ab')2, Fab, and F(ab)2. Also useful are any subfragments retaining the hypervariable,
antigen-binding region of an immunoglobulin and having a size similar to or smaller than a
Fab' fragment. This will include genetically engineered and/or recombinant proteins, whether
single-chain or multiple-chain, which incorporate an antigen-binding site and otherwise
function in vivo as targeting vehicles in substantially the same way as natural
immunoglobulin fragments. Such single-chain binding molecules are disclosed in U.S. Pat.
No. 4,946,778, which is hereby incorporated by reference. Fab' antibody fragments may be
conveniently made by reductive cleavage of F(ab')2 fragments, which themselves may be
made by pepsin digestion of intact immunoglobulin. Fab antibody fragments may be made by
papain digestion of intact immunoglobulin, under reducing conditions, or by cleavage of
F(ab)2 fragments which result from careful papain digestion of whole immunoglobulin.
A ligand or one member of a ligand-receptor binding pair may be conjugated to the
compounds provided herein for targeting the compounds to specific target tissues or target
compositions. Examples of ligand-receptor binding pairs are set out in U.S. Pat. Nos.
4,374,925 and 3,817,837, the teachings of which are incorporated herein by reference.
Many compounds that can serve as targets for ligand-receptor binding pairs, and more
specifically, antibodies, have been identified, and the techniques to construct conjugates of
such ligands with photosensitizers are well known to those of ordinary skill in this art. For
example, Rakestraw et al. teaches conjugating Sn(IV) chlorine6 via covalent bonds to
monoclonal antibodies using a modified dextran carrier (Rakestraw, S. L., Tompkins, R. D.,
and Yarmush, M. L., Proc. Nad. Acad. Sci. USA 87: 4217-4221 (1990). The compounds
disclosed herein may also be conjugated to a ligand, such as an antibody, by using a coupling
agent. Any bond which is capable of linking the components such that they are stable under
physiological conditions for the time needed for administration and treatment is suitable. In
some embodiments, the bond may be a covalent linkage. The link between two components
may be direct, e.g., where a photosensitizer is linked directly to a targeting agent, or indirect,
e.g., where a photosensitizer is linked to an intermediate and that intermediate being linked to
the targeting agent.
A coupling agent should function under conditions of temperature, pH, salt, solvent
system, and other reactants that substantially retain the chemical stability of the
photosensitizer, the backbone (if present), and the targeting agent. Coupling agents should
link component moieties stably, but such that there is only minimal or no denaturation or
deactivation of the photosensitizer or the targeting agent. Many coupling agents react with an
amine and a carboxylate, to form an amide, or an alcohol and a carboxylate to form an ester.
Coupling agents are known in the art (see, e.g., M. Bodansky, "Principles of Peptide
Synthesis", 2nd ed., and T. Greene and P. Wuts, "Protective Groups in Organic Synthesis,"
2nd Ed, 1991, John Wiley, NY).
The compounds or pharmaceutically acceptable derivatives thereof may be packaged
as articles of manufacture containing packaging material and a compound or
pharmaceutically acceptable derivative thereof provided herein, which is effective for
modulating the activity of a skin and/or oral disorder, or for treatment, prevention or
amelioration of one or more symptoms associated with a skin and/or oral disorder or in which
a skin and/or oral disorder is implicated. The articles of manufacture may further comprise a
label that indicates that the compound or composition, or pharmaceutically acceptable
derivative thereof, is used for modulating the activity of a skin and/or oral disorder, or for
treatment, prevention or amelioration of one or more symptoms associated with a skin and/or
oral disorder or in which a skin and/or oral disorder is implicated.
The articles of manufacture provided herein contain packaging materials. Packaging
materials for use in packaging pharmaceutical products are well known to those of skill in the
art. See, e.g., U.S. Pat. Nos. 5,323,907; 5,052,558 and 5,033,252. Examples of
pharmaceutical packaging materials include, but are not limited to, blister packs, bottles,
tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material
suitable for a selected formulation and intended mode of administration and treatment. A
wide array of formulations of the compounds and compositions provided herein are
contemplated as are a variety of treatments for skin and/or oral disorders.
Embodiments of the present invention also provide kits including the elements
necessary to carry out the therapies described above. Such a kit may comprise a carrier being
compartmentalized to receive in close confinement therein one or more containers, such as
tubes or vials. One or more of the containers may contain a compound described herein.
One or more containers may contain one or more enzymes or reagents to be utilized in
desired reactions. These enzymes may be present by.themselves or in admixtures, in
lyophilized form or in appropriate buffers. The kit may contain all of the additional elements
necessary to carry out the methods of the invention.
In some embodiments, a kit of the present invention comprises a first container
comprising a pharmaceutical composition of the present invention. In some embodiments,
the composition comprises a pharmaceutical carrier and a compound of formula (I) or a
prodrug or derivative thereof, and salts thereof.
In some embodiments, the kit may comprise a second pharmaceutical composition,
wherein the second pharmaceutical composition comprises a second pharmaceutical carrier
and a second therapeutic. The kit may separately store the first and second composition,
optionally in separate containers. Any suitable additional therapeutic agent may be present
in the second composition. In some embodiments, the second therapeutic is a therapeutic for
genial warts, herpes (e.g., HSV-1), genital herpes (e.g., HSV-2), and/or herpes zoster
(Shingles). In some embodiments, the second therapeutic is an agent used in antineoplastic
chemotherapy or radiotherapy as described herein.
It is understood that the combinations of all embodiments described herein are also
envisaged in the present invention.
The present invention will now be described in more detail with reference to the
following examples. However, these examples are given for the purpose of illustration and
are not to be construed as limiting the scope of the invention.
Examples
Antineoplastic activity of 15dPMJ2: To evaluate whether 15dPMJ2 is selectively
toxic, tumorigenic (JWF2) and non-tumorigenic (HaCaT) cells were treated with 15dPMJ2
and cell viability was measured. 15dPMJ2 exhibited 4-fold more toxicity towards tumorigenic
keratinocytes at 5µΜ which was utilized in subsequent cell culture studies (Fig. 2). To assess
the in vivo antineoplastic action of 15dPMJ2, the subcutaneous mouse tumor model was
utilized. Melanoma cells were subcutaneously implanted in the flank region of C57BL/6
mice and treated with 0.5 mg/kg 15dPMJ2, vehicle [0.1% DMSO in phosphate buffered saline
(PBS)], or were untreated. 15dPMJ caused a statistically significant reduction in tumor
weight compared to vehicle and untreated animals (Fig. 3A). To determine if 15dPMJ2
induced ER stress the expression of CHOP 10 was detected in the tumor sections. 15dPMJ2
markedly increased CHOP 10 expression in the tumors (Fig. 3B). These findings suggest that
15dPMJ2 will overstimulate the ER stress pathway in HPV-containing cells thereby
facilitating cell death.
Since HPV also activates ER stress, topically applied prostamide 15dPMJ2 may
effectively eliminate cutaneous warts. Cutaneous warts are caused by HPV and include
common warts, plantar warts, flat warts, and genital warts. Cutaneous warts rarely become
malignant in immune competent individuals however, transformation is observed in
individuals with compromised immune systems. Low-risk papillomaviruses (e.g., HPV-1, -2,
-27, and -57) cause cutaneous warts whereas high-risk papillomaviruses (e.g., HPV- 16 and -
18) cause cervical and other epithelial carcinomas. The pathogenesis, prevention, and
treatment of low- and high-risk papillomaviruses have been studied using the cottontail rabbit
papillomavirus (CRPV) model in immunocompetent and immunodeficient animals,
respectively.
The effect of 15dPMJ2 on cutaneous warts will be studied using the CRPV model .
This model has been used for several decades to examine the disease course and therapy of
cutaneous warts (hereafter referred to as papillomas) because it closely recapitulates human
cutaneous papillomatosis pathogenesis. 15dPMJ2 will be topically applied to papillomas and
normal skin to examine its effect on papilloma growth and the health of the animals,
respectively.
We will utilize CRPV DNA with New Zealand White Rabbits {Christensen, ND} to
determine if 15dPMJ2 inhibits the growth and recurrence of papillomas. Rabbits will be
anesthetized and scars formed on the skin to improve CRPV infectivity. Four scarified sites
will be made on the left and right dorsal surface of the skin (total of 8 scars per animal).
CRPV DNA or empty vector (EV) DNA (negative control for papilloma growth) will then be
applied to the scarification sites on day 3 (Figs. 4A-D). Virus DNA concentration
determination: To determine the amount of CRPV DNA needed to form papillomas a
concentration study will be conducted with 10 and 20 g of DNA and papilloma growth
monitored for 3 weeks (Fig. 4B). Drug vehicle identification: To identify the best vehicle for
15dPMJ2 this agent will be dissolved in 1) phosphate buffered saline (PBS)/10% DMSO, 2)
cremophor, or 3) carbomer 940 at a concentration of 0.1 mg/kg/animal. 15dPMJ2 in each
vehicle or the corresponding vehicle will be applied to papillomas 5 days per week for 5
weeks and papilloma growth monitored (Fig. 4C). Therapeutic effect of l5dPMJr . To
determine if 15dPMJ2 causes papilloma regression and/or prevents papilloma recurrence,
different concentrations of 15dPMJ2 in the selected vehicle (or the drug vehicle alone) will be
topically applied to the papillomas (Fig. 4D). As a positive control, salicylic acid, a first-line
wart treatment will also be topically administered. Drug treatment will be conducted for 5
weeks and papilloma growth monitored for three additional weeks to assess recurrence.
Adverse Effects: To examine potential toxicities, 15dPMJ2, salicylic acid, or vehicle will also
be applied to a 2 x 2 cm area of uninvolved skin on papilloma-bearing animals. A
dermatological examination of this skin area will be conducted 24 hours after the last drug
application and at the end of the therapeutic study. Animals will then be euthanized and
papillomas and the uninvolved skin collected for histological examination. To determine if
topically applied 15dPMJ2 causes systemic toxicity the liver, kidneys, spleen, gastrointestinal
tract (GI) and blood will be collected. Tissues will be flash frozen and stored at -80C or fixed
and paraffin embedded.
Virus DNA concentration determination: The concentration of CRPV DNA which
produces papillomas of approximately 1 cm at week 3 will be utilized in the remaining
studies. Empty vector treatment is not expected to result in papilloma formation. Drug
vehicle identification: The drug vehicle which causes the greatest reduction in papilloma
growth with the least amount of toxicity to the uninvolved skin will be selected to study the
therapeutic effect of 15dPMJ2. Therapeutic effect of 15dPMJi: Papillomas that are
statistically significantly smaller in size in 15dPMJ2- compared to vehicle-treated animals
will establish that 15dPMJ2 is an effective therapeutic agent. 15dPMJ2 will be determined to
inhibit recurrence if papilloma size 3 weeks after 15dPMJ2 cessation is statistically
significantly smaller than control group animals. Furthermore, the clinical utility of 15dPMJ2
will be demonstrated if 15dPMJ2 reduces papillomas size to an equal or greater extent than
salicylic acid. Adverse effects: Dermal irritation of the uninvolved skin will be evaluated
using a modified semi-objective, 8-point scale. 15dPMJ2 will be considered non-toxic to the
skin if a statistically significant difference in dermal irritation score is not observed between
15dPMJ2- and vehicle-treated animals within the CRPV and EV treatment groups.
Furthermore, if dermal irritation in salicylic acid treated animals is significantly greater than
in 15dPMJ2 treated animals, 15dPMJ will demonstrate comparable or superior safety to a
clinically utilized agent. Systemic drug toxicity will be evaluated using a five-point semi-
objective scale of toxicity. 15dPMJ2 will be identified as a non-toxic agent if the average
body weight and morphological assessment scores of 15dPMJ2-treated animals are not
statistically significantly different from vehicle-treated animals within the CRPV and EV
treatment groups. Alternative Approaches: If 15dPMJ does not cause papilloma regression
or recurrence, 15dPMJ2 will be co-administered with clinically utilized wart treatments to
assess improved activity. If 15dPMJ2 exhibits significant adverse effects, alternative drug
concentrations and vehicles will be tested.
THAT WHICH IS CLAIMED IS:
1. A method of preventing and/or treating a skin disorder and/or an oral disorder
comprising administering to a subject in need thereof an effective amount of a compound of
formula (I):
or a prodrug or derivative thereof, and salts thereof.
2. The method of claim 1, wherein the prodrug has the following formula:
3. The method of claim 1 or 2, wherein the administration is topical
administration, optionally wherein the administration is transdermal administration.
4 . The method of claim 1 or 2, wherein the administration is by injection and/or
infusion.
5. The method of any one of claims 1-4, wherein the skin disorder and/or oral
disorder is effected by ER stress and/or exhibits increased ER stress.
6. The method of claim 5, wherein the skin disorder and/or oral disorder exhibits
increased ER stress during the growth cycle of skin and/or oral cells (e.g., infected cells).
7. The method of any one of claims 1-6, wherein the skin disorder and/or oral
disorder is a noncancerous skin disorder and/or oral disorder.
8. The method of any one of claims 1-6, wherein the skin disorder and/or oral
disorder is a precancerous skin disorder and/or oral disorder.
9. The method of any one of claims 1-8, wherein the skin disorder is selected
from the group consisting of skin cancer (basal and/or squamous cell carcinoma), acne,
psoriasis, rosacea, seborrheic eczema, hives (allergic and/or idiopathic urticaria), cutaneous
candidiasis (fungi-mediated), carbuncles, cellulitis, impetigo, erysipelas, eczema, cancer
sores (virus-mediated), cold sores, ichthyosis vulgaris, dermatomyositis, acrodermatitis,
sebaceous cyst, keloid, lichen planus, corns, calluses, tinea versicolor, shingles (virus-
mediated), congenital erythropoietic porphyria, dermatitis, contact dermatitis, Darier's
disease, dystrophic epidermolysis bullosa, epidermolysis bullosa simplex, Hailey-hailey
disease, hidradenitis, suppurativa, hirsutism, hyperhidrosis, ichthyosis, keratosis pilaris,
melanoma, pemphigus vulgaris, scabies (mite-mediated), Sweet's syndrome, vitiligo,
pyoderma gangrenosum, warts, and pityriasis lechenoides.
10. The method of any one of claims 1-8, wherein the skin disorder is a
precancerous skin condition selected from the group consisting of actinic keratosis,
hypertrophic actinic keratosis, bowenoid actinic keratosis and actinic cheilitis.
1. The method of any one of claims 1-8, wherein the oral disorder is selected
from the group consisting of cold sores (virus-mediated), canker sores (virus-mediated),
thrush (fungi-mediated), leukoplakia, dry mouth, stomatitis, glossitis, oral lichen planus, oral
cancer, salivary gland stones, salivary gland tumors, pulpitis, dental abscess, gingivitis,
periodontitis, receding gums, gingival hyperplasia and dry socket.
12. The method of any one of claims 1-8, wherein the skin disorder and/or oral
disorder is a human papilloma virus (HPV) (e.g., an HPV that causes cancer and/or warts).
13. The method of any one of claims 1-8, wherein the skin disorder and/or oral
disorder is HPV-1, HPV-2, HPV-27, and/or HPV-57.
14. The method of any one of claims 1-8, wherein the skin disorder and/or oral
disorder is a viral skin and/or oral disease.
15. The method of any one of claims 1-8, wherein the skin disorder and/or oral
disorder is a cutaneous viral infection.
16. The method of any one of claims 1-8, wherein the skin disorder and/or oral
disorder is a herpes simplex virus (HSV).
17. The method of any one of claims 1-8, wherein the skin disorder and/or oral
disorder is a wart (e.g., a common wart, flat wart, filiform wart, mosaic wart, periungual wart,
and/or plantar wart).
18. The method of any one of claims 1-8, wherein the skin disorder is actinic
keratosis.
9. The method of any one of claims 1-18, wherein the method induces cell death
in an ER-stress dependent mechanism.
20. The method of any one of claims 1-19, wherein the method induces cell death
in infected skin and/or oral cells and/or in cells exhibiting increased ER stress (e.g., cells
exhibiting increased ER stress during their growth cycle) compared to normal, healthy cells
of the same type.
2 1. The method of claim 20, wherein the cells are precancerous cells or non¬
cancerous cells.
22. The method of any one of claims 1-21, wherein a pharmaceutical composition
is administered to the subject, the pharmaceutical composition comprising the compound of
formula (I) and a pharmaceutically acceptable carrier.
23. The method of claim 22, wherein the pharmaceutical composition is in the
form of a powder, emulsion, gel, ointment, dispersion, suspension, cream, foam, aerosol,
droplet, an injectable form, or coating.
24. The method of any one of claims 1-23, further comprising administering
(sequentially or concurrently) a second therapeutic.
25. The method of claim 24, wherein the second therapeutic is a therapeutic for
genial warts, herpes (e.g., HSV-1), genital herpes (e.g., HSV-2), and/or herpes zoster
(Shingles).
26. A kit comprising:
a first container comprising a first pharmaceutical composition, wherein the first
pharmaceutical composition comprises a first pharmaceutical carrier and a compound of
formula (
or a prodrug or derivative thereof, and salts thereof.
27. The kit of claim 26, further comprising a second pharmaceutical composition,
wherein the second pharmaceutical composition comprises a second pharmaceutical carrier
and a second therapeutic.
28. The kit of claim 26 or 27, wherein the first pharmaceutical composition and
the second pharmaceutical composition are separately stored in the kit.
29. The kit of any one of claims 26-28, further comprising a second container
comprising the second pharmaceutical composition.
30. The kit of any one of claims 26-29, wherein the first and/or second container
deliver the first and/or second pharmaceutical composition.
31. The kit of any one of claims 27-30, wherein the second therapeutic is a
therapeutic for genial warts, herpes (e.g., HSV-1), genital herpes (e.g., HSV-2), and/or herpes
zoster (Shingles).
32. The kit of any one of claims 27-3 , wherein the second therapeutic is an agent
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